BBU Pharmaceuticals - Intro Deck
12
1 BBU PHARMACEUTICALS, LLC A NEW DRUG FOR PARKINSON’S DISEASE TREATMENT 2013
-
Upload
bdirect2011 -
Category
Business
-
view
618 -
download
7
Transcript of BBU Pharmaceuticals - Intro Deck
1
BBU PHARMACEUTICALS, LLC A NEW DRUG FOR PARKINSON’S DISEASE TREATMENT
2013
2
BDG-DOPAMINE® – a new Parkinson’s disease drug
featuring the direct delivery of dopamine to the brain across the blood-brain barrier based on
the proprietary delivery technology
Game-changing disruption on the market for central nervous system drugs
BDG-DOPAMINE®: nasal spray (or drops)
Substance enabling delivery (“Provider”)
Dopamine Brain capillaries
2-3 min
Brain Dopamine-agonist
(optional)
BBB
!
BLOOD-BRAIN BARRIER (BBB) UNLOCKED
3
Limited efficacy of drug treatment of Parkinson’s disease (PD) PROBLEM
EXECUTIVE SUMMARY: WHY INVEST IN BBU?
BBU PHARMACEUTICALS
SOLUTION BDG-DOPAMINE® offers improvement over major existing drug substance (levodopa)
WHY OUR SOLUTION?
WHY INVEST?
Benefits patients: increased efficacy & fewer side effects
Benefits doctors: wider choice & treatment flexibility
Benefits pharma manufacturers: patent protection & new brand
A
B
C
+
+
Superior product (“proof-of-concept” completed, PCT patents filed)
Underpenetrated market and massive unmet needs
Strong team +
+ Clear exit path through a trade sale
4
PROBLEM: LIMITED EFFICACY OF PD TREATMENT
BBU PHARMACEUTICALS
PD is the 2nd most common adult-onset neurodegenerative disease. A
B
Levodopa Is the only
substance for PD therapy at
advanced stage
Slow, side effects,
diminishing efficacy
No alternative & dearth of new drugs
1 SUBSTANCE WITH LIMITATIONS
NO ALTERNATIVE
No cure, few drugs, limited therapeutical efficacy
5
Fewer side effects
Fast Activaton
1
2
Lower dosage (& lower costs)
Solution to “On-Off” syndrome problem
3
4
BDG-DOPAMINE®
nasal spray Provider Dopamine Brain
capillaries
2-3 min
Brain Dopamine-agonist
(optional)
BBB
“Proof of concept” via physiological and radioisotopic studies on animals
PCT patent application filed in Germany
OUR SOLUTION: BDG-DOPAMINE®
A new drug overcoming shortcomings of Levodopa
Value for Patients vs. Levodopa
Completed Milestones
BBU PHARMACEUTICALS
6
SCALE OF PROBLEM
A
B
C
MARKET SIZE GLOBAL PARKINSON’S
DISEASE DRUG MARKET
PD affects 4+ million people worldwide, mostly in the developed countries with aging population
Global market for PD drugs: US $2.8 – 3.9 billion
Total market CAGR’2011-15: 8.3%
- Levodopa drugs: $0.3-0.5 billion - Dopamine agonists (DA): $0.8-1.1 billion
BDG-DOPAMINE® PLANNED MARKET SHARE
D 10-40% of global levodopa & DA market segments
BBU PHARMACEUTICALS
7
WHY BBU PHARMACEUTICALS?
Highly-acclaimed scientists in the biology, neurology & medicine
TOP-NOTCH TEAM CLEAR BUSINESS MODEL SUCCESSFUL TRACK-RECORD
Dr. Naum Goldstein
PhD; Professor
Proprietary R&D
Alexander Terterov
CEO of BBU
A
B “Proof of concept” completed
C Global patent landscape (patent applications filed in Germany)
D Clear project & exit strategy Built up a successful business around PD drug Parkon® in CIS/CEE;
BBU PHARMACEUTICALS
Science Director of BBU; Participated in Parkon® project
8
Science Director at BBU
Professor; Doctor of Biological Sciences;
NAUM GOLDSTEIN
Professor; Doctor of Biological Sciences
ANDREY KAMENSKY
THE TEAM MAKING IT HAPPEN
Professor of Biophysics; Academician with the Russian Academy of Medical Sciences
YURI VLADIMIROV
Professor; Doctor of Medical Sciences;
GAGIK AVAKYAN
Professor; Doctor of Medical Sciences
GEORGY KOVALEV
CEO of BBU Pharmaceuticals
ALEXANDER TERTEROV
BBU PHARMACEUTICALS
9
KEY PROJECT RISKS
TECHNOLOGY RISKS
REGULATORY RISKS
Novel technology for drug delivery across the blood brain barrier
BBU PHARMACEUTICALS
DESCRIPTION MITIGATION
The technology heavily borrows from Parkon®, a drug admitted to clinical practice in Russia
Complex regulatory bureaucracy related to preclinical and clinical trials
Trials will be carried out in line with GLP standards by service providers cognizant of regulatory approval process in EU and USA
10
FUNDING ROADMAP
Skolkovo grant may cover up to 50% of this
amount
Skolkovo grant may cover up to 50% of this
amount
US $ 2.5 million
US $ 7.5 million
PRE-CLINICAL TRIALS
2013-2014
Pre-clinical trials according to GLP standards
Round A can be broken down into smaller tranches for each step of the trials*
This structure will minimize the risk of misuse and overpayment and ensure maximum transparency to investors
CLINICAL TRIALS
2015-2017
Up to Phase 2a
Clinical trials according to GCP standards
BBU PHARMACEUTICALS
Current Round
Next Round
* - Subject to the agreement with service provider
11
0
20
40
60 US $ million
EXIT STRATEGY & VALUE
8-10 15
INVESTMENTS
COMPANY VALUE & EXIT
MILESTONES
IRR
Players for acquisition Exit
20
60
2.5 US $
million 4.5 3.0
Pre-clinical $ 2.5 m
Phase 0 clinical $1.1 m Phase 1 clinical $3.4 m
Phase 2a clinical
IRR of investor (assuming Skolkovo grant): 70-75% IRR of investor (assuming no grant): 40-45%
BBU PHARMACEUTICALS
12
T
E
+7. 916. 999.90.78
CONTACT INFORMATION
BBU PHARMACEUTICALS
C Nikolay Nazarov Shareholder
T
E
+7.926.811.86.61
C Alexander Terterov
CEO, Founder
